"instanceType","uuid:ID","name","rationale","description","label","id"
"StudyDesign","b688a67d-cc80-4749-b312-fcc505d597cb","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","StudyDesign_1"
